A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2017
Price : $35 *
At a glance
- Drugs Canagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 16 Oct 2017 Last checked against ClinicalTrials.gov record.
- 10 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to IRB review pending IND revision.
- 29 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.